Suppr超能文献

优化药物诱导性心律失常的检测:QT间期与TRIaD。

Refining detection of drug-induced proarrhythmia: QT interval and TRIaD.

作者信息

Shah Rashmi R, Hondeghem Luc M

机构信息

Medicines and Healthcare Products Regulatory Agency, London, UK.

出版信息

Heart Rhythm. 2005 Jul;2(7):758-72. doi: 10.1016/j.hrthm.2005.03.023.

Abstract

QT interval prolongation is so frequently associated with torsades de pointes (TdP) that it has come to be recognized as a surrogate marker of this unique tachyarrhythmia. However, not only does TdP not always follow QT interval prolongation, but TdP can occur even in the absence of a prolonged QT interval. Worse still, even shortening of the QT interval may be associated with serious arrhythmias (particularly ventricular tachycardia [VT] and ventricular fibrillation [VF]). It appears increasingly probable that the distinction between various ventricular tachyarrhythmias may be arbitrary, and drug-induced TdP, polymorphic VT, VT, catecholaminergic polymorphic VT, and VF may represent discrete entities within a spectrum of drug-induced proarrhythmia. Although they are differentiated by the coupling interval and the duration of QT interval, they appear to share a common substrate: a set of disturbances of repolarization characterized by Triangulation, Reverse use dependency, electrical Instability of the action potential, and Dispersion (TRIaD). It is becoming increasingly evident that augmentation of TRIaD, rather than changes in the duration of QT interval, provides the proarrhythmic substrate. In contrast, when not associated with an increase of TRIaD, QT interval prolongation can be an antiarrhythmic property. Electrophysiologically, augmentation of TRIaD can be explained by inhibition of hERG (human ether-a-go-go related gene) channel. Because drug-induced disturbances in repolarization commonly result from inhibition of hERG channels or I(Kr), hERG blockade and the resulting prolongation of QT interval are important properties of a drug to be studied. However, these need only be a concern if associated with TRIaD. More significantly, TRIaD so often precedes prolongation of action potential duration or QT interval and ventricular tachyarrhythmias that it should be considered a marker of proarrhythmia until proven otherwise, even in the absence of QT interval prolongation. Detecting drug-induced augmentation of TRIaD may offer an additional, more sensitive, and accurate indicator of the broader proarrhythmic potential of a drug than may QT interval prolongation alone.

摘要

QT间期延长常与尖端扭转型室速(TdP)相关,以至于它已被视为这种独特快速性心律失常的替代标志物。然而,TdP并非总是紧随QT间期延长之后出现,甚至在QT间期未延长时也可能发生。更糟糕的是,即使QT间期缩短也可能与严重心律失常(尤其是室性心动过速[VT]和心室颤动[VF])相关。越来越有可能的是,各种室性快速性心律失常之间的区分可能是人为的,药物诱导的TdP、多形性VT、VT、儿茶酚胺能多形性VT和VF可能代表药物诱导的心律失常谱中的不同实体。尽管它们通过联律间期和QT间期的持续时间来区分,但它们似乎有一个共同的基础:一组以三角化、反向使用依赖性、动作电位电不稳定和离散度(TRIaD)为特征的复极紊乱。越来越明显的是,TRIaD的增强而非QT间期持续时间的变化提供了心律失常的基础。相比之下,当不伴有TRIaD增加时,QT间期延长可能具有抗心律失常特性。从电生理学角度来看,TRIaD的增强可以通过抑制hERG(人类ether-a-go-go相关基因)通道来解释。由于药物诱导的复极紊乱通常是由hERG通道或I(Kr)的抑制引起的,hERG阻断以及由此导致的QT间期延长是待研究药物的重要特性。然而,只有在与TRIaD相关时才需要关注这些。更重要的是,TRIaD常常在动作电位持续时间或QT间期延长以及室性快速性心律失常之前出现,因此在未被证明不是之前,即使在没有QT间期延长的情况下,也应将其视为心律失常的标志物。检测药物诱导的TRIaD增强可能比单独的QT间期延长提供一个额外的、更敏感和准确的指标,用于指示药物更广泛的心律失常潜力。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验